References:

1. *Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.* Lancet, 2005. **365**(9472): p. 1687-717.

2. Ravdin, P.M., et al., *The decrease in breast-cancer incidence in 2003 in the United States.* N Engl J Med, 2007. **356**(16): p. 1670-4.

3. Howell, A., et al., *Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.* Lancet, 2005. **365**(9453): p. 60-2.

4. Coates, A.S., et al., *Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.* J Clin Oncol, 2007. **25**(5): p. 486-92.

5. Goss, P.E., et al., *Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.* J Natl Cancer Inst, 2005. **97**(17): p. 1262-71.

6. Coombes, R.C., et al., *A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.* N Engl J Med, 2004. **350**(11): p. 1081-92.

7. Gnant M et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. *N Engl J Med* 2009;360(7):679-91.

8. Paik, S., et al., *Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.* J Clin Oncol, 2006. **24**(23): p. 3726-34.

9. Burstein, H. J., A. A. Prestrud, et al. (2010). "American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer." J Clin Oncol **28**(23): 3784-96.

10. Citron, M.L., et al., *Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.* J Clin Oncol, 2003. **21**(8): p. 1431-9.

11. Sparano, J.A., et al., *Weekly paclitaxel in the adjuvant treatment of breast cancer.* New England Journal of Medicine., 2008. **358**(16): p. 1663-71.

12. Fisher, B., et al., *Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.* J Clin Oncol, 1998. **16**(8): p. 2672-85.

13. Hudis, C.A., et al., *Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.* J Clin Oncol, 2007. **25**(15): p. 2127-32.

14. Albain, K. S., W. E. Barlow, et al. (2009). "Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial." Lancet **11**: 55-65.

15. Swain, S. M., J. H. Jeong, et al. (2010). "Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer." N Engl J Med **362**(22): 2053-65.

16. Romond, E. H., E. A. Perez, et al. (2005). "Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer." N Engl J Med **353**(16): 1673-1684.

17. Piccart-Gebhart, M., M. Procter, et al. (2005). "Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer." N Eng J Med **353**(16): 659-72.

18. Buzdar, A. U., V. Valero, et al. (2007). "Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen." Clin Cancer Res **13**(1): 228-33.

19. Fisher, B., A. Brown, et al. (1997). "Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18." Journal of Clinical Oncology **15**(7): 2483-93.

20. Muss, H.B, Berry D., et al (2009). “Adjuvant Chemotherapy in Older Women with Early-Stage Breast Cancer”. N Engl J Med 360:2055-2065.

21. Goss, P.E., Ingle, J. N., et al (2011). “Exemestane for Breast-Cancer Prevention in Postmenopausal Women” N Engl J Med 2011; 364:2381-2391.

22. Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011;365:1273-1283

23. Burstein H, Perez EA, Hortobagyi G, et al. Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines? J Clin Onc 2012; 30(18): 2179-2182

24. Shulman LN, Cirrincione CT, Berry DA, et al, Six Cycles of Doxorubicin and Cyclophosphamide or Paclitaxel Are Not Superior to Four Cycles As Adjuvant Chemotherapy for Breast Cancer in Women With Zero to Three Positive Axillary Nodes: Cancer and Leukemia Group B 40101. J Clin Onc 2012: doi: 10.1200/JCO.2011.40.6405

25. Davies C, Pan H, Godwin J, et al, Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. The Lancet, Volume 381, Issue 9869, Pages 805 - 816, 9 March 2013 doi:10.1016/S0140-6736(12)61963-1

26. American Cancer Society. Cancer Facts & Figures 2014. Atlanta: American Cancer Society; 2014.

27. Shulman, L, Berry DA, Cirrincione CT, et al. Comparison of Doxorubicin and Cyclophosphamide Versus Single-Agent Paclitaxel As Adjuvant Therapy for Breast Cancer in Women With 0 to 3 Positive Axillary Nodes: CALGB 40101 (Alliance) JCO Aug 1, 2014:2311-2317; DOI:10.1200/JCO.2013.53.7142.

28. Pagani O, Regan MM, Walley BA, et al, Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer. NEJM Volume 371(2):107-118 July 10, 2014

29. Berry DA, Hudis CA, Neoadjuvant Therapy in Breast Cancer as a Basis for Drug Approval JAMA Oncol. Published online July 09, 2015. doi:10.1001/jamaoncol.2015.1293